You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Attention Score in Context
| Title |
The Efficacy, Adverse Effects and Economic Implications of Oral Versus Intravenous Methylprednisolone for the Treatment of Optic Neuritis: A Systematic Review
|
|---|---|
| Published in |
Seminars in Ophthalmology, November 2023
|
| DOI | 10.1080/08820538.2023.2287100 |
| Pubmed ID | |
| Authors |
James Pietris, Antoinette Lam, Stephen Bacchi, Aashray K. Gupta, Joshua G. Kovoor, Sumu Simon, Mark Slee, WengOnn Chan |
| Abstract |
Optic neuritis may occur in a variety of conditions, including as a manifestation of multiple sclerosis. Despite significant research into the efficacy of corticosteroids as a first-line treatment, the optimal route of administration has not been well defined. This review aims to explore the efficacy, adverse effects and economic implications of using oral versus intravenous methylprednisolone to treat acute optic neuritis. A systematic search of the databases PubMed/MEDLINE, Embase and CENTRAL was performed to July 2022, prior to data collection and risk of bias analysis in accordance with the PRISMA guidelines. Six articles fulfilled the inclusion criteria. The results showed that in the treatment of acute optic neuritis, oral methylprednisolone has a non-inferior efficacy and adverse effect profile in comparison to intravenous methylprednisolone. In a cost analysis, oral methylprednisolone to be more cost-effective than intravenous methylprednisolone. Oral methylprednisolone has comparable efficacy and adverse effect profiles to intravenous methylprednisolone for the treatment of optic neuritis. The analysis suggests oral administration is more cost-effective than intravenous administration; however, further analyses of the formal cost-benefit ratio are required. |
X Demographics
The data shown below were collected from the profiles of 25 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 3 | 12% |
| United States | 2 | 8% |
| United Kingdom | 2 | 8% |
| Venezuela, Bolivarian Republic of | 1 | 4% |
| France | 1 | 4% |
| Brazil | 1 | 4% |
| Israel | 1 | 4% |
| Philippines | 1 | 4% |
| Mexico | 1 | 4% |
| Other | 4 | 16% |
| Unknown | 8 | 32% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 18 | 72% |
| Practitioners (doctors, other healthcare professionals) | 5 | 20% |
| Scientists | 2 | 8% |
Attention Score in Context
This research output has an Altmetric Attention Score of 17. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 December 2023.
All research outputs
#2,091,610
of 25,397,764 outputs
Outputs from Seminars in Ophthalmology
#6
of 582 outputs
Outputs of similar age
#31,307
of 351,356 outputs
Outputs of similar age from Seminars in Ophthalmology
#1
of 16 outputs
Altmetric has tracked 25,397,764 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 582 research outputs from this source. They receive a mean Attention Score of 2.3. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 351,356 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.